ScreenerHero

CANFCan-Fite BioPharma Ltd.

AMEX · US · Healthcare · Biotechnology · canfite.com
3.330USD-4.31%Mkt Cap: 7.13M $P/E: —

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap7.13M $
Enterprise Value-1.29M $
Revenue (TTM)405.00K $
Gross Profit405.00K $
Net Income (TTM)-9.83M $
Revenue/Share0.4920 USD
Last Price3.330 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-12.33
PEG—
EV/EBITDA0.13
EV/Revenue-3.19
P/S17.62
P/B0.78
EPS (TTM)-10.75
EPS (Forward)-0.27
52W Range
2.5607% of range13.60
52W High13.60 USD
52W Low2.560 USD
Profitability
Gross Margin100.00%
Oper. Margin-2488.67%
EBITDA Margin0.00%
Profit Margin-2426.67%
ROE-175.75%
ROA-103.30%
Growth
Revenue Growth-43.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.95M $
CapEx (TTM)2.00K $
FCF Margin-1231.05%
FCF Yield-69.88%
Net Debt-8.47M $
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity0.01
Current Ratio3.46
Quick Ratio3.13
Book Value/Sh4.272 USD
Cash/Share3.986 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMay 10, 2019
Splits
Last Split1:20
Split DateJan 5, 2026
Analyst Consensus
Rating—
Target (Mean)8.000 USD
Upside (mean)+140.2%
Target Range8.000 USD – 8.000 USD
# Analysts1
Ownership
Shares Out.2.14M
Float2.14M
Insiders0.00%
Institutions2.44%
Short Interest
Short Ratio0.0d
Short % Float3.10%
Short % Out.3.08%
Shares Short66.09K
Short (prev mo.)321.50K
Technical
SMA 503.256 (+2.3%)
SMA 2004.144 (-19.6%)
Beta-0.04
S&P 52W Chg18.16%
Avg Vol (30d)87.04K
Avg Vol (10d)34.74K
Technical Indicators
RSI (14)50.0
MACD0.0473
MACD Signal0.0335
MACD Hist.+0.0138
BB Upper3.585 USD
BB Middle3.303 USD
BB Lower3.021 USD
BB Width17.07%
ATR (14)0.2109 USD
Vol Ratio (20d)0.69x